These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4433477)

  • 1. A painful bleeding syndrome associated with increased fibrinolytic activity.
    Rowell NR
    Br J Dermatol; 1974 Nov; 91(5):591-6. PubMed ID: 4433477
    [No Abstract]   [Full Text] [Related]  

  • 2. Massive bleeding with fibrinolysis: management with heparin and epsilon aminocaproic acid.
    Bergin JJ; Crosby WH; Jahnke EJ
    Mil Med; 1966 Apr; 131(4):340-4. PubMed ID: 4955920
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic hyperfibrinolysis associated with amyloidosis: clinical response to epsilon amino caproic acid.
    Chang JC; Kane KK
    Am J Clin Pathol; 1984 Mar; 81(3):382-7. PubMed ID: 6702732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIBRINOLYTIC BLEEDING AND ITS MANAGEMENT.
    SHERRY S; FLETCHER AP; ALKJAERSIG N
    Ann N Y Acad Sci; 1964 Jul; 115():481-92. PubMed ID: 14192857
    [No Abstract]   [Full Text] [Related]  

  • 5. Amniotic fluid embolism. A case investigated by coagulation and fibrinolysis studies.
    Skjodt P
    Acta Obstet Gynecol Scand; 1965; 44(3):437-57. PubMed ID: 5863077
    [No Abstract]   [Full Text] [Related]  

  • 6. CIRCULATING FIBRINOLYTIC ACTIVATOR AND HEMORRHAGIC DIATHESIS.
    ENDE N; AUDITORE JV
    Ann Surg; 1963 Jul; 158(1):117-25. PubMed ID: 14042622
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinolysis: an unusual cause of bleeding.
    Porter GH
    Med Clin North Am; 1967 Jul; 51(4):1061-72. PubMed ID: 5339067
    [No Abstract]   [Full Text] [Related]  

  • 8. [EXISTENCE OF CHANGES IN HEMOSTASIS WITH DECREASED FIBRINOLYSIS. BASIS FOR THE HEMOSTATIC TREATMENT WITH EPSILON AMINOCAPROIC ACID IN NON FIBRINOLYTIC HEMORRHAGIC DIATHESIS].
    CASTILLO R; SERRANO J; CARALPS A; VINAS M
    Med Clin (Barc); 1963 Oct; 41():302-6. PubMed ID: 14125259
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibrinolysis produced by contact with a caterpillar.
    Arocha-Piñango CL; Layrisse M
    Lancet; 1969 Apr; 1(7599):810-2. PubMed ID: 4180365
    [No Abstract]   [Full Text] [Related]  

  • 10. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia.
    Rosenberg RD; Colman RW; Lorand L
    Br J Haematol; 1974 Feb; 26(2):269-84. PubMed ID: 4843743
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time.
    Brodsky I; Dennis LH
    Am J Clin Pathol; 1966 Jan; 45(1):61-9. PubMed ID: 5904206
    [No Abstract]   [Full Text] [Related]  

  • 12. Inherited fibrinolytic hyperactivity.
    Self J; Matthews C
    Arch Intern Med; 1968 Oct; 122(4):357-8. PubMed ID: 5676420
    [No Abstract]   [Full Text] [Related]  

  • 13. Six new cases of a caterpillar-induced bleeding syndrome.
    Arocha-Piñango CL; de Bosch NB; Torres A; Goldstein C; Nouel A; Argüello A; Carvajal Z; Guerrero B; Ojeda A; Rodriguez A
    Thromb Haemost; 1992 Apr; 67(4):402-7. PubMed ID: 1378651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disorders in the blood coagulation of patients with mesenchymal dysplasias].
    Barkagan ZS; Peregudova IG; Sukhanova GA; Solomina TI
    Gematol Transfuziol; 1993 May; 38(5):28-30. PubMed ID: 8034168
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of accelerated fibrinolysis in liver disease.
    Francis RB; Feinstein DI
    Haemostasis; 1984; 14(6):460-5. PubMed ID: 6534818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INHIBITION OF FIBRINOLYSIS AND FIBRINOGENOLYSIS IN MAN: COMPARISON OF EPILSON-AMINOCAPROIC AID AND KALLIKREIN INHIBITOR.
    BECK E; SCHMUTZLER R; DUCKERT F
    Thromb Diath Haemorrh; 1963 Nov; 10():106-19. PubMed ID: 14081273
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage.
    Marder VJ; Shulman NR; Carroll WR
    Trans Assoc Am Physicians; 1967; 80():156-67. PubMed ID: 4230117
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnosis and treatment of intravascular coagulation processes].
    Moriau M; Masure R
    Nouv Rev Fr Hematol; 1968; 8(1):5-19. PubMed ID: 4232151
    [No Abstract]   [Full Text] [Related]  

  • 19. [Disorders of hemostasis and fibrinolysis in hemorrhagic erysipelas].
    Cherkasov VIa; Bokarev IN; Babakulieva TKh; Dynkina IM; Detinkina GN; Nesterova SG; Smolianitskiĭ AIa; Nakisbekova GO
    Sov Med; 1989; (10):105-8. PubMed ID: 2617332
    [No Abstract]   [Full Text] [Related]  

  • 20. Bleeding tendency of unknown origin and protein Z levels.
    Gamba G; Bertolino G; Montani N; Spedini P; Balduini CL
    Thromb Res; 1998 Jun; 90(6):291-5. PubMed ID: 9700859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.